RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
La Jolla Pharmaceutical Stock

La Jolla Pharmaceutical Stocks 2024

La Jolla Pharmaceutical Stocks

34.18 M

Ticker

LJPC

ISIN

US5034596040

WKN

A1XB6B

In 2024, La Jolla Pharmaceutical had 34.18 M outstanding stocks, a 0% change from the 34.18 M stocks in the previous year.

The La Jolla Pharmaceutical Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2026e34.18
2025e34.18
2024e34.18
2023e34.18
2022e34.18
202134.18
202027.33
201927.11
201825.42
201721.22
201617.23
201515.65
201410.67
20131.54
20120.2
20110.01
2010-
2009-
2008-
2007-
2006-
2005-
2004-
2003-
2002-

La Jolla Pharmaceutical shares outstanding

The number of shares was La Jolla Pharmaceutical in 2023 — This indicates how many shares 34.179 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue La Jolla Pharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates La Jolla Pharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of La Jolla Pharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating La Jolla Pharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

La Jolla Pharmaceutical Aktienanalyse

What does La Jolla Pharmaceutical do?

La Jolla Pharmaceutical Co is a biopharmaceutical company specializing in the development and marketing of medicines for the treatment of rare and severe diseases. It was founded in 1989 in San Diego, California, by physician and scientist Ivor Royston. The company's business model is focused on researching, developing, and marketing drugs for patients with rare or severe diseases. The company prioritizes the needs and requirements of patients and aims to tailor each medication to maximize effectiveness. La Jolla's main focus is on researching medications for severe and rare diseases such as sepsis, acute kidney failure, and lung inflammation. These medications are intended to help patients who have limited or no treatment options. The company's portfolio includes various drugs, with antibodies being an important component for the treatment of inflammation and autoimmune diseases. Notably, Giapreza is one of the company's well-known medications approved by the FDA in December 2017, designed to treat adult patients with severe or most severe septic shock by increasing blood pressure. LJPC-401 is another significant medication developed by La Jolla Pharmaceutical Co, intended for the treatment of lupus nephritis, an autoimmune-related kidney inflammation that affects about 50% of systemic lupus erythematosus (SLE) patients. The company is also working on the development of a medication for migraine treatment, aiming to reduce the severity and frequency of migraine attacks. Overall, La Jolla Pharmaceutical Co has made significant progress in expanding its research activities and is committed to developing innovative medications to improve the lives of patients with rare and severe diseases. The company's focus on patient needs has proven to be a strategic advantage, positioning it competitively for the future. La Jolla Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating La Jolla Pharmaceutical's Shares Outstanding

La Jolla Pharmaceutical's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in La Jolla Pharmaceutical’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding La Jolla Pharmaceutical’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in La Jolla Pharmaceutical’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about La Jolla Pharmaceutical stock

How many stocks are there of La Jolla Pharmaceutical?

The current number of stocks of La Jolla Pharmaceutical is 34.18 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of La Jolla Pharmaceutical are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of La Jolla Pharmaceutical evolved in recent years?

The number of shares of La Jolla Pharmaceutical has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. La Jolla Pharmaceutical as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of La Jolla Pharmaceutical?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does La Jolla Pharmaceutical pay?

Over the past 12 months, La Jolla Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, La Jolla Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of La Jolla Pharmaceutical?

The current dividend yield of La Jolla Pharmaceutical is .

When does La Jolla Pharmaceutical pay dividends?

La Jolla Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of La Jolla Pharmaceutical?

La Jolla Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of La Jolla Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is La Jolla Pharmaceutical located?

La Jolla Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von La Jolla Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of La Jolla Pharmaceutical from 10/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/24/2024.

When did La Jolla Pharmaceutical pay the last dividend?

The last dividend was paid out on 10/24/2024.

What was the dividend of La Jolla Pharmaceutical in the year 2023?

In the year 2023, La Jolla Pharmaceutical distributed 0 USD as dividends.

In which currency does La Jolla Pharmaceutical pay out the dividend?

The dividends of La Jolla Pharmaceutical are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The La Jolla Pharmaceutical stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von La Jolla Pharmaceutical

Our stock analysis for La Jolla Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of La Jolla Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.